Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-3120 intravesical monotherapy in high-risk non-muscle invasive bladder cancer with carcinoma in situ
NL-OMON59160Phase 2Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Mar 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of MK-3120 in non-muscle-invasive bladder cancer (NMIBC) and urothelial carcinoma in situ (CIS), sponsored by Merck & Co. Primary endpoints: Number of participants who experience a dose-limiting toxicity, Number of participants who experience one or more adverse events and 1 more. Started Mar 2026; status: active, not recruiting.
02
Drugs
MK-3120
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)urothelial carcinoma in situ (CIS)
Beyond the preview
Go deeper on NL-OMON59160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59160.